Pune, India, August 2021/MRFR Press Release: Market Research Future has published its half-cooked research report on the全球护理点诊断/测试市场.
妈rket Highlights
根据MRFR分析，预计全球护理点诊断/测试市场将从2021年注册到2021年的CAGR〜11.6％，持有2027年的价值〜36,740.3百万美元。
The global point of care diagnostics/testing market is driven by several factors, such as increasing demand for remote diagnosis, rising demand for early-stage diagnosis products, and growing demand for minimally or non-invasive diagnostic products. Other factors such as the introduction of mobile healthcare technologies and wearable diagnostic devices, the emergence of new technologies for monitoring and imaging are creating opportunities for the market players.
The market players are involved in various strategic collaborations, mergers & acquisitions, product launches, cooperative development of the product, and investing in stock to expand their worldwide presence. For instance, in July 2020, Becton, Dickinson and Company (US) launched a rapid POC antigen test to diagnose SARS-CoV-2 in 15 minutes. In June 2020, Celltrion Group (South Korea) announced to launch COVID-19 POC antigen testing kit. Furthermore, the prominent players focus on employee satisfaction, transforming their research utilities, and diversifying their distribution network. These factors will augment the market growth and will increase the market share during the forecast period.
Access full report @https://www.marketreesearchfuture.com/reports/point-of-care-diagnostics-testing-market-10642.
Regional Analysis
据估计，由于对虚拟和方便的诊断解决方案的需求日益增加，医疗保健法规，越来越多，以及对年轻人中的健康和医疗保健的提高，据估计，北美占据了护理诊断/测试市场。此外，the involvement/adoption of strategies like mergers & acquisitions by key players, government partnerships, and the development of new products are also推动市场增长。
欧洲拥抱第二位置point of care diagnostics/testing market due to the increasing number of IVD testing, molecular diagnostics, and the prevalence of respiratory diseases across the region. The industry players are involved in various business activities such as product launches, mergers and acquisitions, partnerships, and other commercial approaches. For instance, in May 2020, ProciseDx (US) launched 510k filing for CRP test in Europe for gastrointestinal disorders. The product launch aims to offer high lab-quality results to the patients. In addition, in July 2021, QuantuMDx (Singapore) launched Q-POC, a point-of-care diagnostics to detect SARS-CoV-2. The product is easy to use, affordable, and offers results in 30 minutes. Such business parameters are expected to propel the point of care diagnostic market in the forecast period.
Asia-Pacific is projected to be the fastest-growing regional market during the study period due to increasing demand for diagnostic tests such as blood gas tests, rapid blood coagulation tests, pregnancy tests, drug abuse screening, rapid diagnosis of cardiac markers, blood glucose testing, electrolyte analysis, urine analysis, and dry biochemical tests across the region. In addition, the increasing demand for multiple diagnostic devices coupled with the rising demand for accurate and efficient diagnostic and testing devices is driving the Asia-Pacific point of care diagnostics market.
由于HBA1C的诊断日益增加以及对糖化血红蛋白分析的需求不断增长，世界其他地区的市场增长在过去几年中取得了重要性。此外，该地区的Covid-19案例的数量上升是支持POCS诊断的需求。此外，增加了对医疗保健设备制造设施的投资正在加强区域和全球医疗保健提供者的产品组合。南美洲对体外诊断的升级需求正在推动整个地区POC的销售额。预计此类因素将在评估期内增加市场增长。
Segmentation
The global point of care diagnostics/testing market is categorized into product, end user, mode of purchase, and platform. Based on the product category, the market has been segregated into glucose monitoring, pregnancy & fertility testing, infectious disease testing, drug abuse testing, coagulation monitoring, cardiometabolic monitoring, cancer/tumor marker testing, hematology testing, urinalysis testing, cholesterol, and others. The glucose monitoring segment is expected to hold a considerable share of the market in 2020. Increasing POC urine hCG (Human Chorionic Gonadotropin) tests to diagnose pregnancy is fueling the market growth. Companies such as Abbott (US) are offering total β-hCG for the early detection of pregnancy. In addition, rising POC testing for early tumor detection is strengthening the demand for POC diagnostic products.
Based on end user, the global point of care diagnostics/testing market has been classified as hospitals & clinics, diagnostics centers, homecare/self-testing, and others. Hospitals &clinics held the largest segment share in 2020, owing to easy maneuvering, sample processing, and quick delivery of results. A laboratory information system also manages and stores patient’s test data for further reference, which further drives the market growth. Additionally, the demand for homecare/self-testing is accelerating due to increasing health risks during the pandemic outbreak and rising connectivity between patients and health care providers.
基于购买方式，全局护理点诊断/测试市场被归类为柜台上的（OTC）测试产品和基于处方的测试产品。OTC测试产品旨在在购买类别模式下持有更大的市场份额。OTC产品出售，没有仿古疾病诊断患者的处方。它们包括某些参数，其中包括最高标准的疗效和安全性，良好的制造实践（GMP）制造，稳定性测试和21张CFR 201.66下的标签。据FDA介绍，超过300,000个营销的OTC药品分为80个治疗课程。产品的古爱和可用性正在推动护理点诊断/测试市场。
Based on the platform, the global point of care diagnostics/testing market has been classified as immunoassays, molecular diagnostics, dipstick, and others. Immunoassays is estimated to hold the largest segment share in 2020, owing to the increasing demand forthe products for testing particular antibodies or a specific antigen in blood or other body fluids. The immunoassays-based POC test is carried out in countries with low resources and facilities. Among the immunoassays, lateral flow immunoassays are highly used for quick diagnosis as they are sensitive to specific antigens and offer quick & accurate results.
关键人物;主力;重要一员
Some of the key players in the global point of care diagnostics/testing market are Abbott Laboratories (US), Siemens Healthineers GmbH (Germany), Chembio Diagnostics, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Becton, Dickinson and Company (US), Danaher Corporation (US), PTS Diagnostics (US), Nova Biomedical (US), Quidel Corporation (US), Sekisui Diagnostics (US), Trinity Biotech (Ireland), AccuBioTech Co., Ltd.(China), Instrumentation Laboratory Company (Werfen) (US), and EKF Diagnostics Holdings plc (UK) among others.